Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

19.650
-0.990-4.80%
Volume:2.27M
Turnover:44.12M
Market Cap:22.36B
PE:-122.61
High:19.910
Open:19.880
Low:19.060
Close:20.640
52wk High:27.280
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:0.50
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.160
ROE:-26.91%
ROA:-14.75%
PB:4.69
PE(LYR):-122.61
PS:6.34

Loading ...

US Stock Moves: Zai Lab Shares Surge Over 10% Extending Two-Day Rally

Stock News
·
Aug 07

Hong Kong Stocks Close: Hang Seng Rises 0.54%, Tech Index Gains 0.78%, PCB Concept Shares Surge, Biotech Stocks Rally, Z.AI Jumps Over 14%

Deep News
·
Aug 07

Movement Alert|ZAI LAB Rises 15.9% in Regular Trading, Q2 Product Revenue Up 11% QoQ with Multiple H2 Catalysts Ahead

Market Focus
·
Aug 07

Hong Kong Market Movers: Innovative Drug Stocks Rally as Earnings Season Approaches, Medical Conferences Expected to Provide Catalysts

Stock News
·
Aug 07

Positive Catalysts Drive Surge in Innovative Drug Sector; WuXi Series Leads as Huabao's Hong Kong Stock Connect Medical ETF Jumps 3%

Deep News
·
Aug 07

Zai Lab's Hong Kong Shares Hit Three-Month High on Quarterly Revenue Beat

Reuters
·
Aug 07

Hong Kong Market Movers: Zai Lab Ltd (09688) Surges Over 13% on Q2 Product Revenue Growth and Promising Pipeline Catalysts

Stock News
·
Aug 07

Zai Lab Ltd 2026 Second Quarter Product Revenue Rises 11% Sequentially as Zoci and ZL-1503 Lead Global Pipeline Acceleration

Stock News
·
Aug 06

Zai Lab Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Zai Lab Q2 FY26 Net Loss Widens to $50.83 Million; Revenue Slips 3% to $106.31 Million Year over Year

Reuters
·
Aug 06

Zai Lab - Q2 2026 Net Loss $50.80 Mln, Loss Per Share $0.05, Loss Per Ads $0.46

THOMSON REUTERS
·
Aug 06

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

THOMSON REUTERS
·
Aug 06

Zai Lab - Q2 2026 Total Revenue $106.30 Mln vs $110 Mln in Q2 2025

THOMSON REUTERS
·
Aug 06

Zai Lab Reports Flat Share Count for July 2026; 1.14 B Issued Shares, No New Equity Raised

Bulletin Express
·
Aug 06

Zai Lab Says FDA Grants Orphan Drug Designation for DLL3 ADC Zocilurtatug Pelitecan in Neuroendocrine Carcinomas

Reuters
·
Aug 03

Earning Preview: ZAI LAB Q2 revenue expected to decline by 16.16%, institutions lean cautious on profitability trajectory

Earnings Agent
·
Jul 31

China's domestic innovative drugs set for overseas revenue breakthrough as policy support strengthens

Stock News
·
Jul 31

Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

MT Newswires Live
·
Jul 29

Zai Lab Sets 6 Aug Audit Committee Review and Immediate Release of 2026 Interim Results

Bulletin Express
·
Jul 24

Movement Alert|ZAI LAB Falls 5.05% in Regular Trading, Multiple Banks Cut Target Prices Amid Biotech Sector Weakness

Market Focus
·
Jul 24